Phosphomannose Isomerase (PMI) Inhibitor

MLS0315771 is a potent and biologically active competitive phosphomannose isomerase (MPI) inhibitor, with an IC₅₀ ~1 μM and a K_i of 1.4 μM.

ML089 is an orally active inhibitor of phosphomannose isomerase (PMI) and PHOSPHO1, with an IC₅₀ value of 1.3 μM against human PMI and an IC₅₀ value of 0.8 μM against PHOSPHO1. ML089 blocks the catabolism of mannose-6-phosphate, directs mannose-6-phosphate to participate in protein glycosylation, increases mannose incorporation into cellular proteins, and reduces tritiated water production from mannose-6-phosphate. ML089 inhibits PMI in living cells. ML089 can be used in research related to congenital disorder of glycosylation type Ia (CDG-Ia).

Thr101 is an inhibitor (IC₅₀=2.9 μM) of phosphomannose isomerase (PMI).PMI can compete with phosphomannose mutase 2 (PMM2) for the binding site of Man-6-P and convert mannose-6-phosphate (Man-6-P) into fructose-6-phosphate (Fru-6-P) .Thr101 only specifically inhibits PMI and not PMM2. Thr101 can be used for research of congenital disorder of glycosylation type Ia (CDG-Ia).